Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-B167 +/- Tislelizumab in Advanced Solid Tumors
NCT05644626Phase 1Withdrawn
- Sponsor
- BeiGene
- Start
- Mar 2024
- Primary completion
- Mar 2025
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
01
Overview
Phase 1, open-label trial of BGB-B167 in solid tumor (2 arms), sponsored by BeiGene. Primary endpoints: Number of Participants with Adverse Events and Serious Adverse Events at 30 months, Number of Participants Experiencing AEs Meeting Protocol-defined Dose-limiting Toxicity Criteria at 24 months and 2 more. Planned start Mar 2024; status: withdrawn.
02
Drugs
BGB-B167
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05644626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05644626.